Feasibility of Self-administered Neuromodulation for Neurogenic Bladder in Spinal Cord Injury
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To determine if self-administered transcutaneous tibial nerve stimulation (TTNS) is a feasible treatment option for neurogenic bladder among people with spinal cord injury (SCI) who utilize intermittent catheterization for bladder management. Methods: Four-week observational trial in chronic SCI subjects performing intermittent catheterization with incontinence episodes using TTNS at home daily for 30 minutes. Those using anticholinergic bladder medications were given a weaning schedule to begin at week 2. Primary outcomes were compliance and satisfaction. Secondary outcomes included change in bladder medications, efficacy based on bladder diary, adverse events, and incontinence quality of life (I-QoL) survey. Results: All 16 subjects who started the study completed the 4-week trial rating TTNS with high satisfaction and easy to use, without discomfort. Twelve of 14 patients (86%) using anticholinergic bladder medications reduced their dosage and maintained similar frequency and volumes of bladder catheterization and incontinence episodes. Bladder medication reduced by approximately 3.2 mg weekly (95% confidence interval, -5.9 to -0.4) and anticholinergic side effects of dry mouth and drowsiness decreased more than 1 level of severity from baseline (P=0.027, P=0.015, respectively). At 4 weeks, total I-QoL score improved by an average of 3.2 points compared to baseline in all domains. Conclusions: This pilot trial suggests TTNS is feasible to be performed at home in people with chronic SCI. Participants were able to reduce anticholinergic medication dosage and anticholinergic side effects while maintaining continence, subsequently improving QoL scores. These results advocate for further randomized, controlled trials with longer duration and urodynamic evaluation to assess long-term efficacy.
Abstract
Purpose: To determine if self-administered transcutaneous tibial nerve stimulation (TTNS) is a feasible treatment option for neurogenic bladder among people with spinal cord injury (SCI) who utilize intermittent catheterization for bladder management. Methods: Four-week observational trial in chronic SCI subjects performing intermittent catheterization with incontinence episodes using TTNS at home daily for 30 minutes. Those using anticholinergic bladder medications were given a weaning schedule to begin at week 2. Primary outcomes were compliance and satisfaction. Secondary outcomes included change in bladder medications, efficacy based on bladder diary, adverse events, and incontinence quality of life (I-QoL) survey. Results: All 16 subjects who started the study completed the 4-week trial rating TTNS with high satisfaction and easy to use, without discomfort. Twelve of 14 patients (86%) using anticholinergic bladder medications reduced their dosage and maintained similar frequency and volumes of bladder catheterization and incontinence episodes. Bladder medication reduced by approximately 3.2 mg weekly (95% confidence interval, -5.9 to -0.4) and anticholinergic side effects of dry mouth and drowsiness decreased more than 1 level of severity from baseline (P=0.027, P=0.015, respectively). At 4 weeks, total I-QoL score improved by an average of 3.2 points compared to baseline in all domains. Conclusions: This pilot trial suggests TTNS is feasible to be performed at home in people with chronic SCI. Participants were able to reduce anticholinergic medication dosage and anticholinergic side effects while maintaining continence, subsequently improving QoL scores. These results advocate for further randomized, controlled trials with longer duration and urodynamic evaluation to assess long-term efficacy.
참고문헌 (30)
- Ackery A, "A global perspective on spinal cord injury epidemiology", J Neurotrauma, 21, pp.1355~1370 (2004)
- Weld KJ, "Association of level of injury and bladder behavior in patients with post-traumatic spinal cord injury", Urology, 55, pp.490~494 (2000)
- Anderson KD, "Targeting recovery : priorities of the spinal cord-injured population", J Neurotrauma, 21, pp.1371~1383 (2004)
- Anderson KD, "Session 3: with us, not for us: community activity and priorities", SCI 2020: launching a decade for disruption in spinal cord injury research (2019)
- Bacsu CD, "Diagnosing detrusor sphincter dyssynergia in the neurological patient", BJU Int, 109(Suppl 3), pp.31~34 (2012)
- Consortium for Spinal Cord Medicine, "Bladder management for adults with spinal cord injury : a clinical practice guideline for health-care providers", J Spinal Cord Med, 29, pp.527~573 (2006)
- del Popolo G, "Controversy over the pharmacological treatments of storage symptoms in spinal cord injury patients : a literature overview", Spinal Cord, 50, pp.8~13 (2012)
- Stöhrer M, "EAU guidelines on neurogenic lower urinary tract dysfunction", Eur Urol, 56, pp.81~88 (2009)
- Gray SL, "Cumulative use of strong anticholinergics and incident dementia : a prospective cohort study", JAMA Intern Med, 175, pp.401~407 (2015)
- Risacher SL, "Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults", JAMA Neurol, 73, pp.721~732 (2016)
- Fougere RJ, "Reduction in bladder-related autonomic dysreflexia after onabotulinumtoxinA treatment in spinal cord injury", J Neurotrauma, 33, pp.1651~1657 (2016)
- Cruz F, "Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity : a randomised, double-blind, placebo-controlled trial", Eur Urol, 60, pp.742~750 (2011)
- "BOTOX (onabotulinumtoxinA)", Allergan Pharmaceuticals Ireland, ~ (2011)
- Tanagho EA, "Bladder pacemaker : scientific basis and clinical future", Urology, 20, pp.614~619 (1982)
- Tanagho EA, "Neural stimulation for control of voiding dysfunction: a preliminary report in 22 patients with serious neuropathic voiding disorders", J Urol, 142(2 Pt 1), pp.340~345 (1989)
- Sievert KD, "Early sacral neuromodulation prevents urinary incontinence after complete spinal cord injury", Ann Neurol, 67, pp.74~84 (2010)
- McGuire EJ, "Treatment of motor and sensory detrusor instability by electrical stimulation", J Urol, 129, pp.78~79 (1983)
- Canbaz Kabay S, "Lvong term sustained therapeutic effects of percutaneous posterior tibial nerve stimulation treatment of neurogenic overactive bladder in multiple sclerosis patients : 12-months results", Neurourol Urodyn, 36, pp.104~110 (2017)
- Gupta P, "Percutaneous tibial nerve stimulation and sacral neuromodulation : an update", Curr Urol Rep, 16, pp.4~ (2015)
- Gaziev G, "Percutaneous Tibial Nerve Stimulation(PTNS)efficacy in the treatment of lower urinary tract dysfunctions : a systematic review", BMC Urol, 13, pp.61~ (2013)
- Sirls ER, "Percutaneous tibial nerve stimulation in the office setting : real-world experience of over 100 patients", Urology, 113, pp.34~39 (2018)
- Chen G, "The possible role of percutaneous tibial nerve stimulation using adhesive skin surface electrodes in patients with neurogenic detrusor overactivity secondary to spinal cord injury", Int Urol Nephrol, 47, pp.451~455 (2015)
- de Sèze M, "Transcutaneous posterior tibial nerve stimulation for treatment of the overactive bladder syndrome in multiple sclerosis : results of a multicenter prospective study", Neurourol Urodyn, 30, pp.306~311 (2011)
- Stampas A, "Safety, feasibility, and efficacy of transcutaneous tibial nerve stimulation in acute spinal cord injury neurogenic bladder : a randomized control pilot trial", Neuromodulation, 22, pp.716~722 (2019)
- Amarenco G, "Urodynamic effect of acute transcutaneous posterior tibial nerve stimulation in overactive bladder", J Urol, 169, pp.2210~2215 (2003)
- Finazzi Agrò E, "Posterior tibial nerve stimulation : is the once-a-week protocol the best option?", Minerva Urol Nefrol, 57, pp.119~123 (2005)
- American Urogynecologic Society(AUGS)Guidelines Committee, "AUGS consensus statement : association of anticholinergic medication use and cognition in women with overactive bladder", Female Pelvic Med Reconstr Surg, 23, pp.177~178 (2017)
- Kim A, "Health related quality of life in patients with side-effects after antimuscarinic treatment for overactive bladder", Low Urin Tract Symptoms, 9, pp.171~175 (2017)
- Sanford MT, "Neuromodulation in neurogenic bladder", Transl Androl Urol, 5, pp.117~126 (2016)
- Welk B, "A pilot randomized-controlled trial of the urodynamic efficacy of mirabegron for patients with neurogenic lower urinary tract dysfunction", Neurourol Urodyn, 37, pp.2810~2817 (2018)